HC Wainwright & Co. Maintains Buy on Blueprint Medicines, Raises Price Target to $85
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andrew Fein maintains a Buy rating on Blueprint Medicines (NASDAQ:BPMC) and raises the price target from $75 to $85.
May 23, 2023 | 10:11 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Blueprint Medicines and raises the price target from $75 to $85.
The raised price target by HC Wainwright & Co. analyst Andrew Fein indicates a positive outlook for Blueprint Medicines. This news is likely to have a positive short-term impact on the stock price as it shows increased confidence in the company's potential growth and performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100